First Time Loading...

Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT

Watchlist Manager
Arcturus Therapeutics Holdings Inc Logo
Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT
Watchlist
Price: 32.86 USD 2.27% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. [ Read More ]

The intrinsic value of one ARCT stock under the Base Case scenario is 114.87 USD. Compared to the current market price of 32.86 USD, Arcturus Therapeutics Holdings Inc is Undervalued by 71%.

Key Points:
ARCT Intrinsic Value
Base Case
114.87 USD
Undervaluation 71%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Arcturus Therapeutics Holdings Inc

Backtest ARCT Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ARCT stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of Arcturus Therapeutics Holdings Inc's business.

What risks and challenges
does Arcturus Therapeutics Holdings Inc face in the near future?

Summarize the latest earnings report
of Arcturus Therapeutics Holdings Inc.

Provide P/E
for Arcturus Therapeutics Holdings Inc and its competitors.

Financials

Balance Sheet Decomposition
Arcturus Therapeutics Holdings Inc

Current Assets 386.6m
Cash & Short-Term Investments 292m
Receivables 32.1m
Other Current Assets 62.5m
Non-Current Assets 42.8m
PP&E 40.9m
Other Non-Current Assets 1.9m
Current Liabilities 78.9m
Accounts Payable 5.3m
Accrued Liabilities 31.9m
Other Current Liabilities 41.7m
Non-Current Liabilities 68.9m
Other Non-Current Liabilities 68.9m
Efficiency

Earnings Waterfall
Arcturus Therapeutics Holdings Inc

Revenue
169.9m USD
Operating Expenses
-245m USD
Operating Income
-75.1m USD
Other Expenses
48.5m USD
Net Income
-26.6m USD

Free Cash Flow Analysis
Arcturus Therapeutics Holdings Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ARCT Profitability Score
Profitability Due Diligence

Arcturus Therapeutics Holdings Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
ROE is Increasing
ROIC is Increasing
31/100
Profitability
Score

Arcturus Therapeutics Holdings Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

ARCT Solvency Score
Solvency Due Diligence

Arcturus Therapeutics Holdings Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Average Altman Z-Score
54/100
Solvency
Score

Arcturus Therapeutics Holdings Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ARCT Price Targets Summary
Arcturus Therapeutics Holdings Inc

Wall Street analysts forecast ARCT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ARCT is 68.98 USD with a low forecast of 18.18 USD and a high forecast of 147 USD.

Lowest
Price Target
18.18 USD
45% Downside
Average
Price Target
68.98 USD
110% Upside
Highest
Price Target
147 USD
347% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ARCT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ARCT Price
Arcturus Therapeutics Holdings Inc

1M 1M
-18%
6M 6M
+29%
1Y 1Y
+112%
3Y 3Y
-17%
5Y 5Y
+406%
10Y 10Y
-75%
Annual Price Range
32.86
52w Low
15.5
52w High
42.99
Price Metrics
Average Annual Return 91.55%
Standard Deviation of Annual Returns 203.65%
Max Drawdown -90%
Shares Statistics
Market Capitalization 881.6m USD
Shares Outstanding 26 915 200
Percentage of Shares Shorted 20.97%

ARCT Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Arcturus Therapeutics Holdings Inc Logo
Arcturus Therapeutics Holdings Inc

Country

United States of America

Industry

Biotechnology

Market Cap

881.6m USD

Dividend Yield

0%

Description

Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. The company is headquartered in San Diego, California and currently employs 177 full-time employees. The company went IPO on 2013-05-22. The firm is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its mRNA platform, the Company's lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose levels. The firm's products under developmental stage using STARR technology are ARCT-021, ARCT-154 and ARCT-165. Its COVID-19 vaccine candidate, ARCT-021, which is based on its STARR technology platform is through Phase II clinical trials. Its LUNAR-FLU Vaccine consists of Liver Franchise ARCT-810 (LUNAR-OTC) and Lung Franchise ARCT-032 (LUNAR-CF).

Contact

CALIFORNIA
San Diego
10628 Science Center Dr Ste 250
+18589002660.0
https://arcturusrx.com/

IPO

2013-05-22

Employees

177

Officers

Founder, President, CEO & Director
Mr. Joseph E. Payne M.Sc.
Founder, Chief Scientific Officer, COO & Secretary
Dr. Padmanabh Chivukula
CFO & Director
Mr. Andrew H. Sassine MBA
Senior VP of Finance & Corporate Controller
Mr. Keith C. Kummerfeld CPA
Vice President and Head of IR/PR & Marketing
Ms. Neda Safarzadeh
Chief Legal Officer
Mr. Lance Kurata
Show More
Chief Human Resources Officer
Ms. Natash O. Bowman
Chief Business Officer
Mr. Kevin T. Skol
Chief Medical Officer
Dr. Juergen Froehlich FCPh, M.D., MBA
Chief Development Officer
Dr. Igor Smolenov M.D., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one ARCT stock?

The intrinsic value of one ARCT stock under the Base Case scenario is 114.87 USD.

Is ARCT stock undervalued or overvalued?

Compared to the current market price of 32.86 USD, Arcturus Therapeutics Holdings Inc is Undervalued by 71%.